Skip to main content

Table 2 Change from baseline: IND/GLY vs SFC in men and women with COPD

From: Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

 

Treatment difference (IND/GLY vs SFC)

Men

n = 2550

P value

Women

n = 804

P value

Trough FEV1 (mL) (LSM [95% CI])

67 (51–84)

< 0.001

42 (12–71)

0.006

SGRQ-C total score (LSM [95% CI])

−1.3 (−2.3– −0.4)

0.007

−1.1 (−2.8–0.7)

0.230

Proportion of patients with MCID (≥4 units) in SGRQ-C (OR [95% CI])

1.29 (1.09–1.54)

0.004

1.32 (0.96–1.83)

0.093

Rescue medication use (puffs/day) (LSM [95% CI])

−0.27 (− 0.43– − 0.12)

< 0.001

− 0.18 (− 0.45–0.09)

0.189

  1. The analyses were performed in the full analysis set from the FLAME study, based on data availability. Data are presented as LSM. b.i.d. twice daily, CI confidence interval, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, IND/GLY indacaterol/glycopyrronium 110/50 μg o.d., LSM least squares mean, MCID minimal clinically important difference, o.d. once daily, OR odds ratio, SFC salmeterol/fluticasone 50/500 μg b.i.d., SGRQ-C St. George’s Respiratory Questionnaire for COPD